Cryoport Opens New 1,300 sq.m. IntegriCell Facility in Belgium for Cell Therapy

• Cryoport’s new IntegriCell facility in Belgium aims to support cell therapy with cryopreservation services.

• The 1,300-square-meter site has capacity for over 1,100 leukapheresis products annually, strengthening Cryoport’s European capabilities.

Cryoport, Inc., a global supply chain solutions provider for life sciences, has opened its new IntegriCell™ facility in Belgium to support cell therapy programs with cryopreservation services. The facility, located in Villers-le-Bouillet, aims to enhance the cryopreservation of leukapheresis materials, providing a key resource for the development and commercialisation of cell-based therapies.

The 1,300-square-meter, GMP-compliant site is Cryoport’s European Centre of Excellence, expanding its capabilities to develop, optimise, and standardise cryogenic preservation methods for cell therapy products. IntegriCell’s services are intended to improve manufacturing efficiency and scalability, addressing the growing need for high-quality, cryopreserved leukapheresis materials within the industry.

“Our new IntegriCell Belgium facility extends our global reach and strengthens our ability to deliver consistent, high-quality cryopreservation solutions for the cell therapy community,” said Jerrell Shelton, CEO of Cryoport. He noted that the facility, along with the company’s site in Houston, will help Cryoport standardise cryopreservation processes for cell-based therapies across different locations.

The new facility will initially have the capacity to preserve over 1,100 leukapheresis products each year, providing a reliable and consistent supply of cryopreserved leukopaks to cell therapy developers across Europe. With room for future expansion, Cryoport’s IntegriCell facility is positioned to adapt to evolving market demands and client requirements.